OncoMatch/Clinical Trials/NCT04402151
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Is NCT04402151 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC for prostate cancer.
Treatment: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC — This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C OR GREATER, T2B (UNFAVORABLE INTERMEDIATE RISK)
Excluded: Stage METASTATIC DISEASE, PELVIC LYMPH NODES
Grade: Gleason 8-10tertiary component 5Gleason 4+3=7Gleason 7 (Gleason)
Gleason 8-10 or tertiary component 5 disease and/or PSA of 20 ng/ml or greater and/or Tumor stage of T2c or greater; OR Unfavorable intermediate risk (Gleason 4+3=7, >50% of cores involved, or 2 or more intermediate risk factors which include Gleason 7 disease, PSA 10-20, or T2b disease)
Demographics
Prior therapy
Cannot have received: abiraterone (abiraterone)
Patients on or intending to take abiraterone will be excluded
Cannot have received: radiation therapy
history of prior radiation to the prostate
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Weill Cornell Medicine · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04402151 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior abiraterone, radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage T2C OR GREATER or T2B (UNFAVORABLE INTERMEDIATE RISK) is required.
Is there an age limit?
Yes. Patients must be 90 years or younger and at least 21 years old.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages